Thrombosis Drugs Market Forecast up to 2024
Thrombosis Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview:
Thrombosis refers to the medical term used for the development of blood clot within a blood vessel. The condition occurs when a blood clot forms and blocks an artery or a vein, stopping or blocking the flow of blood. Thrombosis drugs are used to treat or prevent the formation of blood clot, which can cause diverse thrombotic events. The drugs for the treatment of thrombosis include anticoagulants and thrombin inhibitor drugs. These drugs reduce the clotting power of the blood, and subsequently the probabilities of the disease events. The various disease conditions treated with thrombosis drugs include deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation. According to the estimation of Thrombosis UK, every 6 seconds an individual dies from VTE globally, that is 1 in 4 people die due to reasons related to blood clots. According to the estimation of Centers for Disease Control and Prevention, there are around 900,000 people afflicted by DVT or pulmonary embolism; also, 1 or 2 per 1,000 individuals each year are affected in the US.
The market for thrombosis drugs is driven by an upsurge in the burden of cardiovascular disease & trauma cases and increasing geriatric & obese population. The increase in the launch of novel drugs in the market and research activities to develop innovative drugs provide an opportunity for enhanced and effective treatment, which is expected to support the market growth in the next five years. However, side effects allied with thrombosis drugs and less awareness among the public about thromboembolism conditions may slow down the growth of the market.
Market Analysis: The “global thrombosis drugs market” is estimated to witness a CAGR of 9.5% during the forecast period 2018–2024. The market is analyzed based on three segments – drug class, indication, and regions.
Drug Class Analysis: The thrombosis drugs market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor segment occupied a significant market share in 2017 and is expected to grow at a high CAGR during the forecast period. The high preference of anticoagulant drug usage is expected to boost the segment growth during the forecast period.
Indication Analysis: The thrombosis drugs market by indication is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. The pulmonary embolism segment occupied a significant share in 2017 and is anticipated to grow at a high CAGR during the forecast period. Increasing focus on the development of low-cost drugs and large patient pool with pulmonary embolism condition are likely to propel the market growth in the next five years.
Region Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global thrombosis drugs market, followed by Europe. The availability of novel anticoagulants, the presence of dominant market players, increased disease awareness, and rising healthcare expenditure make North America a dominant shareholder in the market. Asia Pacific is the fastest growing region due to an upsurge in the prevalence of cardiovascular disease & other age-related chronic diseases, growing healthcare expenditure, and increasing access to healthcare services.
Key Players:
Johnson & Johnson, Aspen Pharmacare Holdings, Sanofi S.A., Bayer AG, Boehringer Ingelheim, and Bristol–Myers Squibb are the key players in the market. Few of the predominate players in the market include AstraZeneca plc, Daiichi Sankyo, Pfizer, Inc., and Baxter International Inc.
Competitive Analysis:
Due to the increasing demand for thrombosis drugs in recent years, many companies are collaborating to develop novel drugs, and new thrombosis drugs have been launched and approved globally. For instance, in December 2017, Aurobindo Pharma received FDA approval to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent DVT. Janssen Pharmaceuticals, in late 2017, announced the launch of XARELTO (rivaroxaban) for reducing the sustained risk of recurrent venous thromboembolism (VTE). In June 2017, Portola launched its drug betrixaban (Bevyxxa) in the US market. In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor and backup compounds.
Benefits: The report provides complete details about the products offered by thrombosis drugs companies in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Overview:
Thrombosis refers to the medical term used for the development of blood clot within a blood vessel. The condition occurs when a blood clot forms and blocks an artery or a vein, stopping or blocking the flow of blood. Thrombosis drugs are used to treat or prevent the formation of blood clot, which can cause diverse thrombotic events. The drugs for the treatment of thrombosis include anticoagulants and thrombin inhibitor drugs. These drugs reduce the clotting power of the blood, and subsequently the probabilities of the disease events. The various disease conditions treated with thrombosis drugs include deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation. According to the estimation of Thrombosis UK, every 6 seconds an individual dies from VTE globally, that is 1 in 4 people die due to reasons related to blood clots. According to the estimation of Centers for Disease Control and Prevention, there are around 900,000 people afflicted by DVT or pulmonary embolism; also, 1 or 2 per 1,000 individuals each year are affected in the US.
The market for thrombosis drugs is driven by an upsurge in the burden of cardiovascular disease & trauma cases and increasing geriatric & obese population. The increase in the launch of novel drugs in the market and research activities to develop innovative drugs provide an opportunity for enhanced and effective treatment, which is expected to support the market growth in the next five years. However, side effects allied with thrombosis drugs and less awareness among the public about thromboembolism conditions may slow down the growth of the market.
Market Analysis: The “global thrombosis drugs market” is estimated to witness a CAGR of 9.5% during the forecast period 2018–2024. The market is analyzed based on three segments – drug class, indication, and regions.
Drug Class Analysis: The thrombosis drugs market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor segment occupied a significant market share in 2017 and is expected to grow at a high CAGR during the forecast period. The high preference of anticoagulant drug usage is expected to boost the segment growth during the forecast period.
Indication Analysis: The thrombosis drugs market by indication is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. The pulmonary embolism segment occupied a significant share in 2017 and is anticipated to grow at a high CAGR during the forecast period. Increasing focus on the development of low-cost drugs and large patient pool with pulmonary embolism condition are likely to propel the market growth in the next five years.
Region Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global thrombosis drugs market, followed by Europe. The availability of novel anticoagulants, the presence of dominant market players, increased disease awareness, and rising healthcare expenditure make North America a dominant shareholder in the market. Asia Pacific is the fastest growing region due to an upsurge in the prevalence of cardiovascular disease & other age-related chronic diseases, growing healthcare expenditure, and increasing access to healthcare services.
Key Players:
Johnson & Johnson, Aspen Pharmacare Holdings, Sanofi S.A., Bayer AG, Boehringer Ingelheim, and Bristol–Myers Squibb are the key players in the market. Few of the predominate players in the market include AstraZeneca plc, Daiichi Sankyo, Pfizer, Inc., and Baxter International Inc.
Competitive Analysis:
Due to the increasing demand for thrombosis drugs in recent years, many companies are collaborating to develop novel drugs, and new thrombosis drugs have been launched and approved globally. For instance, in December 2017, Aurobindo Pharma received FDA approval to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent DVT. Janssen Pharmaceuticals, in late 2017, announced the launch of XARELTO (rivaroxaban) for reducing the sustained risk of recurrent venous thromboembolism (VTE). In June 2017, Portola launched its drug betrixaban (Bevyxxa) in the US market. In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor and backup compounds.
Benefits: The report provides complete details about the products offered by thrombosis drugs companies in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 Pharmaceutical spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Causes of thrombosis
3.3 Risk factors for thrombosis
3.4 Symptoms of thrombosis
3.5 Diagnosis of thrombosis
3.6 Segmented Addressable Market (SAM)
3.7 Trends of the thrombosis drugs market
3.8 Related Markets
3.8.1 Over-the-Counter (OTC) drugs
Market Trends
3.8.2 Cardiovascular drugs
Market Trends
3.8.3 Respiratory drugs
Market Trends
4 MARKET OUTLOOK
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Thrombosis Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing burden of cardiovascular disease and trauma cases across the globe
5.1.1.2 Upsurge in the geriatric and obese population
5.1.2 Opportunities
5.1.2.1 Increase in health care spending and demand for better treatment in emerging economies
5.1.2.2 Increasing new product launch and R&D activities
5.1.3 Restraints
5.1.3.1 Side effects associated with thrombosis drugs
5.1.3.2 Lack of awareness among about thromboembolism conditions
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 DRUG CLASS: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Factor Xa Inhibitors
6.3 Low Molecular Weight Heparin
6.4 P2Y12 platelet inhibitors
7 INDICATIONS: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Deep vein thrombosis (DVT)
7.3 Pulmonary embolism
7.4 Atrial fibrillation
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 Aspen Pharmacare Holdings Limited
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategy
10.2 Johnson & Johnson
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Sanofi S.A.
10.3.1 Overview
10.3.2 Business Units
10.3.3 Geographic Presence
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 Boehringer Ingelheim GmbH
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategy
10.5 Bayer AG
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Presence
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategy
10.6 Bristol-Myers Squibb
10.6.1 Overview
10.6.2 Geographic Presence
10.6.3 Business Focus
10.6.4 SWOT Analysis
10.6.5 Business Strategy
11 COMPANIES TO WATCH FOR
11.1 AstraZeneca plc
11.1.1 Overview
11.1.2 AstraZeneca plc: Recent Developments
11.2 Pfizer, Inc.,
11.2.1 Overview
11.2.2 Pfizer, Inc.: Recent Developments
11.3 Baxter International Inc
11.3.1 Overview
11.3.2 Baxter International Inc: Recent Developments
11.4 Daiichi Sankyo
11.4.1 Overview
11.4.2 Daiichi Sankyo: Recent Developments
12 ANNEXURE
12.1 Abbreviations
1.1 Industry overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 Pharmaceutical spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Causes of thrombosis
3.3 Risk factors for thrombosis
3.4 Symptoms of thrombosis
3.5 Diagnosis of thrombosis
3.6 Segmented Addressable Market (SAM)
3.7 Trends of the thrombosis drugs market
3.8 Related Markets
3.8.1 Over-the-Counter (OTC) drugs
Market Trends
3.8.2 Cardiovascular drugs
Market Trends
3.8.3 Respiratory drugs
Market Trends
4 MARKET OUTLOOK
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Thrombosis Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing burden of cardiovascular disease and trauma cases across the globe
5.1.1.2 Upsurge in the geriatric and obese population
5.1.2 Opportunities
5.1.2.1 Increase in health care spending and demand for better treatment in emerging economies
5.1.2.2 Increasing new product launch and R&D activities
5.1.3 Restraints
5.1.3.1 Side effects associated with thrombosis drugs
5.1.3.2 Lack of awareness among about thromboembolism conditions
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 DRUG CLASS: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Factor Xa Inhibitors
6.3 Low Molecular Weight Heparin
6.4 P2Y12 platelet inhibitors
7 INDICATIONS: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Deep vein thrombosis (DVT)
7.3 Pulmonary embolism
7.4 Atrial fibrillation
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 Aspen Pharmacare Holdings Limited
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategy
10.2 Johnson & Johnson
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Sanofi S.A.
10.3.1 Overview
10.3.2 Business Units
10.3.3 Geographic Presence
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 Boehringer Ingelheim GmbH
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategy
10.5 Bayer AG
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Presence
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategy
10.6 Bristol-Myers Squibb
10.6.1 Overview
10.6.2 Geographic Presence
10.6.3 Business Focus
10.6.4 SWOT Analysis
10.6.5 Business Strategy
11 COMPANIES TO WATCH FOR
11.1 AstraZeneca plc
11.1.1 Overview
11.1.2 AstraZeneca plc: Recent Developments
11.2 Pfizer, Inc.,
11.2.1 Overview
11.2.2 Pfizer, Inc.: Recent Developments
11.3 Baxter International Inc
11.3.1 Overview
11.3.2 Baxter International Inc: Recent Developments
11.4 Daiichi Sankyo
11.4.1 Overview
11.4.2 Daiichi Sankyo: Recent Developments
12 ANNEXURE
12.1 Abbreviations
LIST OF TABLES
Table 1 GLOBAL THROMBOSIS DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 2 OTHER PROMINENT VENDORS OF THROMBOSIS DRUGS MARKET
Table 3 ASPEN PHARMACARE HOLDINGS LIMITED: OFFERINGS
Table 4 ASPEN PHARMACARE HOLDINGS LIMITED: RECENT DEVELOPMENTS
Table 5 JOHNSON & JOHNSON: OFFERINGS
Table 6 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 7 SANOFI S.A.: PRODUCT OFFERINGS
Table 8 SANOFI S.A.: RECENT DEVELOPMENTS
Table 9 BOEHRINGER INGELHEIM: PRODUCT OFFERINGS
Table 10 BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS
Table 11 BAGER AG: PRODUCT OFFERINGS
Table 12 BAYER AG: RECENT DEVELOPMENTS
Table 13 BRISTOL-MYERS SQUIBB: OFFERINGS
Table 14 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
Table 15 ASTRAZENECA PLC: SNAPSHOT
Table 16 PFIZER, INC.: SNAPSHOT
Table 17 BAXTER INTERNATIONAL INC: SNAPSHOT
Table 18 DAIICHI SANKYO: SNAPSHOT
Table 1 GLOBAL THROMBOSIS DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 2 OTHER PROMINENT VENDORS OF THROMBOSIS DRUGS MARKET
Table 3 ASPEN PHARMACARE HOLDINGS LIMITED: OFFERINGS
Table 4 ASPEN PHARMACARE HOLDINGS LIMITED: RECENT DEVELOPMENTS
Table 5 JOHNSON & JOHNSON: OFFERINGS
Table 6 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 7 SANOFI S.A.: PRODUCT OFFERINGS
Table 8 SANOFI S.A.: RECENT DEVELOPMENTS
Table 9 BOEHRINGER INGELHEIM: PRODUCT OFFERINGS
Table 10 BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS
Table 11 BAGER AG: PRODUCT OFFERINGS
Table 12 BAYER AG: RECENT DEVELOPMENTS
Table 13 BRISTOL-MYERS SQUIBB: OFFERINGS
Table 14 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
Table 15 ASTRAZENECA PLC: SNAPSHOT
Table 16 PFIZER, INC.: SNAPSHOT
Table 17 BAXTER INTERNATIONAL INC: SNAPSHOT
Table 18 DAIICHI SANKYO: SNAPSHOT
LIST OF CHARTS
Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)
Chart 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)
Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017
Chart 5 RESEARCH METHODOLOGY OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 6 GLOBAL THROMBIS DRUGS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 7 SEGMENTATION OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 8 PEST ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 9 PORTER 5 FORCES ON GLOBAL THROMBOSIS DRUGS MARKET
Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 11 KEY STAKEHOLDERS
Chart 12 GLOBAL THROMBOSIS DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2017 (%)
Chart 13 GLOBAL THROMBOSIS DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2024 (%)
Chart 14 GLOBAL FACTOR XA INHIBITORS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 15 GLOBAL LOW MOLECULAR WEIGHT HEPARIN MARKET FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL P2Y12 PLATELET INHIBITORS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 17 GLOBAL THROMBOSIS DRUGS MARKET BY INDICATION SEGMENTATION, 2017 (%)
Chart 18 GLOBAL THROMBOSIS DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 19 GLOBAL THROMBOSIS DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2024 (%)
Chart 20 THROMBOSIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 21 THROMBOSIS DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 22 THROMBOSIS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION)
Chart 23 THROMBOSIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 24 ASPEN PHARMACARE HOLDINGS LIMITED: OVERVIEW SNAPSHOT
Chart 25 ASPEN PHARMACARE HOLDINGS: BUSINESS UNITS
Chart 26 ASPEN PHARMACARE HOLDINGS: GEOGRAPHIC PRESENCE
Chart 27 ASPEN PHARMACARE HOLDINGS: SWOT ANALYSIS
Chart 28 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 29 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 30 JOHNSON & JOHNSON: GEOGRAPHIC PRESENCE
Chart 31 : SWOT ANALYSIS
Chart 32 SANOFI S.A.: OVERVIEW SNAPSHOT
Chart 33 SANOFI S.A.: BUSINESS UNITS
Chart 34 SANOFI S.A.: GEOGRAPHIC PRESENCE
Chart 35 SANOFI S.A.: SWOT ANALYSIS
Chart 36 BOEHRINGER INGELHEIM: OVERVIEW SNAPSHOT
Chart 37 BOEHRINGER INGELHEIM: BUSINESS UNITS
Chart 38 BOEHRINGER INGELHEIM: GEOGRAPHIC PRESENCE
Chart 39 BOEHRINGER INGELHEIM: SWOT ANALYSIS
Chart 40 BAYER AG: OVERVIEW SNAPSHOT
Chart 41 BAYER AG: BUSINESS UNITS
Chart 42 BAYER AG: GEOGRAPHIC PRESENCE
Chart 43 BAYER AG: SWOT ANALYSIS
Chart 44 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
Chart 45 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
Chart 46 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
Chart 47 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)
Chart 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)
Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017
Chart 5 RESEARCH METHODOLOGY OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 6 GLOBAL THROMBIS DRUGS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 7 SEGMENTATION OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 8 PEST ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 9 PORTER 5 FORCES ON GLOBAL THROMBOSIS DRUGS MARKET
Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET
Chart 11 KEY STAKEHOLDERS
Chart 12 GLOBAL THROMBOSIS DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2017 (%)
Chart 13 GLOBAL THROMBOSIS DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2024 (%)
Chart 14 GLOBAL FACTOR XA INHIBITORS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 15 GLOBAL LOW MOLECULAR WEIGHT HEPARIN MARKET FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL P2Y12 PLATELET INHIBITORS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 17 GLOBAL THROMBOSIS DRUGS MARKET BY INDICATION SEGMENTATION, 2017 (%)
Chart 18 GLOBAL THROMBOSIS DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 19 GLOBAL THROMBOSIS DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2024 (%)
Chart 20 THROMBOSIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 21 THROMBOSIS DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 22 THROMBOSIS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION)
Chart 23 THROMBOSIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 24 ASPEN PHARMACARE HOLDINGS LIMITED: OVERVIEW SNAPSHOT
Chart 25 ASPEN PHARMACARE HOLDINGS: BUSINESS UNITS
Chart 26 ASPEN PHARMACARE HOLDINGS: GEOGRAPHIC PRESENCE
Chart 27 ASPEN PHARMACARE HOLDINGS: SWOT ANALYSIS
Chart 28 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 29 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 30 JOHNSON & JOHNSON: GEOGRAPHIC PRESENCE
Chart 31 : SWOT ANALYSIS
Chart 32 SANOFI S.A.: OVERVIEW SNAPSHOT
Chart 33 SANOFI S.A.: BUSINESS UNITS
Chart 34 SANOFI S.A.: GEOGRAPHIC PRESENCE
Chart 35 SANOFI S.A.: SWOT ANALYSIS
Chart 36 BOEHRINGER INGELHEIM: OVERVIEW SNAPSHOT
Chart 37 BOEHRINGER INGELHEIM: BUSINESS UNITS
Chart 38 BOEHRINGER INGELHEIM: GEOGRAPHIC PRESENCE
Chart 39 BOEHRINGER INGELHEIM: SWOT ANALYSIS
Chart 40 BAYER AG: OVERVIEW SNAPSHOT
Chart 41 BAYER AG: BUSINESS UNITS
Chart 42 BAYER AG: GEOGRAPHIC PRESENCE
Chart 43 BAYER AG: SWOT ANALYSIS
Chart 44 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
Chart 45 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
Chart 46 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
Chart 47 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
